DecisionRx, a value-based healthcare company focused on reducing the cost of care by helping physicians optimise prescribing decisions for their patients, has agreed a a $100m credit facility with global investment firm Carlyle.
As part of the transaction, which was led by Carlyle’s credit strategic solutions team, a group within the global credit business focused on private fixed income and asset-backed investments, Carlyle has secured the option to acquire 25% of the outstanding equity of DecisionRx.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
The financing will support DecisionRx in delivering medication therapy optimisation to patients of accountable care organisations, Medicare Advantage plans, and self-insured employers. The facility is expected to fund lab testing and comprehensive medication reviews by DecisionRx pharmacists for over 100,000 patients.
Aon Securities served as an advisor to DecisionRx in arranging the financing.
Source: Private Equity Wire
Can’t stop reading? Read more
EQT leads $5.5bn Galderma share sale in record Swiss secondary exit
EQT leads $5.5bn Galderma share sale in record Swiss secondary exit EQT and its co-investors have...
CVC reports record performance as €205bn private markets platform expands
CVC reports record performance as €205bn private markets platform expands CVC Capital Partners...
Brookfield explores $1.3bn acquisition of EQT and PAI-backed World Freight Company
Brookfield explores $1.3bn acquisition of EQT and PAI-backed World Freight Company Brookfield...